Association of NT-proBNP With Clinical Outcomes in Patients Undergoing Transcatheter Tricuspid Valve Intervention

Figures

• 

  Figure 1. Kaplan-Meier Curves for All-Cause Mortality by NT-proBNP Tertiles After Transcatheter Tricuspid Valve Intervention This figure illustrates all-cause mortality stratified by baseline NT-proBNP tertiles in patients undergoing TTVI. Survival probabilities were estimated using the Kaplan-Meier method and compared using the log-rank test. Increasing baseline NT-proBNP tertiles were associated with a stepwise increase in mortality, with the highest tertile exhibiting the poorest long-term survival. NT-proBNP = N-terminal pro-B-type natriuretic peptide.

• 

  Figure 2. Kaplan-Meier Curves for All-Cause Mortality by baseline NT-proBNP Tertiles Among Patients With Intraprocedural Success After Transcatheter Tricuspid Valve Intervention This figure illustrates all-cause mortality stratified by baseline NT-proBNP tertiles in patients with intraprocedural success undergoing TTVI. Survival probabilities were estimated using the Kaplan-Meier method and compared using the log-rank test. Increasing baseline NT-proBNP tertiles remained associated with a stepwise increase in mortality despite successful intervention, with the highest tertile exhibiting the poorest long-term survival. Abbreviation as in Figure 1.

• 

  Figure 3. Kaplan-Meier Curves for All-Cause Mortality According to 4-Week NT-proBNP Trajectory After Transcatheter Tricuspid Valve Intervention Kaplan-Meier survival curves illustrate all-cause mortality stratified by early NT-proBNP trajectory at 4 weeks after TTVI, categorized as decreasing or increasing NT-proBNP levels. Survival distributions were compared using the log-rank test. Patients with increasing NT-proBNP at early follow-up exhibited significantly worse long-term survival, identifying a high-risk subgroup despite intervention. Abbreviation as in Figure 1.

• 

  Central Illustration. Association of NT-proBNP With Clinical Outcomes in Patients Undergoing Transcatheter Tricuspid Valve Intervention In this single-center cohort, 339 consecutive patients undergoing TTVI between 2018 and 2023 were screened, of whom 293 fulfilled eligibility criteria and were included in the final analysis. Patients with tricuspid regurgitation undergoing TTVI showed an increased hazard for all-cause mortality with higher baseline NT-proBNP values, independent of relevant clinical and echocardiographic parameters. This prognostic association persisted even among patients with intraprocedural success. At 4-week follow-up, patients with increasing NT-proBNP concentrations demonstrated significantly worse long-term survival compared with patients showing decreasing values. Early postprocedural NT-proBNP assessment may therefore help identify patients at high-risk for long-term outcomes. NT-proBNP = N-terminal pro-B-type natriuretic peptide; TTVI = transcatheter tricuspid valve intervention; TEER = transcatheter edge-to-edge repair.